Klin Farmakol Farm. 2005;19(1):40-42

Drug interactions between warfarin and cardiovascular drugs

David Suchý, MUDr. Zdenka Poklopová
Oddělení klinické farmakologie, FN Plzeň

Warfarin is a member of a class of vitamin K antagonists and acts as an inhibitor of epoxide reductase and vitamin K reductase, two essential enzymes in vitamin K cycle. It is a racemic mixture of enantiomers which have different pharmacokinetic and pharmacodynamic properties. Due to its metabolism warfarin is susceptible to many drug interactions on different bases. Clinically most important interactions are those due to inhibition of its hepatic metabolism. Awareness of the interactions between warfarin and other medications may help to avoid the risk of excessive or inadequate anticoagulation.

Keywords: Key words: warfarin, pharmacodynamics, pharmacokinetics, drug interactions.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Suchý D, Poklopová Z. Drug interactions between warfarin and cardiovascular drugs. Klin Farmakol Farm. 2005;19(1):40-42.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Penka M. Perorální antikoagulační léčba. Int Med pro praxi. 2003; 4: 3-6.
    2. Řehulková O. Interactions of warfarin. Biomed. Papers 2001; 145: 27-38. Go to original source...
    3. Matýšková M, Penka M. Interakce antikoagulačních léků s potravinami a potravinovými doplňky. Int Med pro praxi. 2000; 5: 20-23.
    4. Weiss P, Halkin H, Seligsohn U.Decline of protein C and S and factors II,VII and X during the initiation of warfarin therapy. Thromb Res 1987; 45 (6): 783-790. Go to original source... Go to PubMed...
    5. Špinar J, Vítovec J, Kubecová I, Parenica J. Klinické studie v kardiologii. Grada Publishing, Praha 2001: 244.
    6. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med. 1994; 121(9): 676-683. Go to original source... Go to PubMed...
    7. Cropp JS et al. A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacotherapy.1997; 5: 917-928.
    8. Udall J.Drug interference with warfarin therapy. Clin Med. 1970; 77: 20.
    9. Almog S, Shafran N, Halkin H, Weiss P, Farfel Z, Martinowitz U, Bank H. Mechanism of warfarin potentiation by amiodarone: dose- and concentration-dependent inhibition of warfarin elimination. Eur J Clin Pharmacol 1985; 28: 257-261. Go to original source... Go to PubMed...
    10. Widimský J. Nežádoucí účinky amiodaronu. Cor Vasa 2000; 42 (5): 235-242.
    11. Stocley IH. Drug interactions, 4th editon. London: The Pharmaceutical Press. 1996.
    12. Bax NDS, Lennard MS, Al Asady S et al. Inhibition of drug metabolism by beta adrenoreceptor antagonists.
    13. Bax ND, Lennard MS, Tucker GT et al. The effect of beta adrenoreceptor antagonists an the pharmacokinetics and pharmacodynamics of warfarin after single dose. Br J Clin Pharmacol. 1984; 17 (5): 553-557. Go to original source... Go to PubMed...
    14. Kousalová L, Baranová J, Anzenbacher P. Lékové interakce na úrovni cytochromů P450 - část I. Interakce na úrovni CYP3A4. Klin Farmakol Farm. 2003; 17: 151-157.
    15. Chan TYK. Adverse interactions between warfarin and nonsteroidal antiinflamatory drugs: mechanism, clinical significance, and avoidance. Ann Pharmacother. 1995; 29: 1274-1283. Go to original source... Go to PubMed...
    16. Takase K, Fujioka H, Ogasawara M, Anuoma M, Tameda Y, Nakano T, Koasaka Y. Drug induced hepatitis during combination therapy of warfarin potazium and ticlopidine chloride. Mie Med J 1990; 40: 27-32.
    17. Gaw A. Wosornu D. Simvasatatin during warfarin therapy in hyperlipoproteinemia. Lancet 1992; 340: 979-980. Go to original source... Go to PubMed...
    18. Neuvonen PJ. Simvastatin but not pravastatin is very susceptible to interaction with the CYP 3A4 inhibited with itroconazole. Clin Pharm Therap 1998; 63: 332-341. Go to original source... Go to PubMed...
    19. Ascah KJ et al. Interaction between fenofibrate and warfarin.Ann Pharmacother 1998; 32: 765-768. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.